Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Keytruda pembrolizumab advanced or metastatic
malignant pleural mesothelioma (MPM)
Pending
Keytruda pembrolizumab Non-small cell lung cancer (NSCLC) Active
Keytruda pembrolizumab Non-Small Cell Lung Cancer, neoadjuvant Active
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Reimburse with clinical criteria and/or conditions Active
Keytruda pembrolizumab Biliary tract carcinoma Reimburse with clinical criteria and/or conditions Active
Keytruda pembrolizumab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Reimburse with clinical criteria and/or conditions Active
Keytruda pembrolizumab Unresectable or metastatic MSI-H or dMMR solid tumors Active
Keytruda pembrolizumab Esophageal carcinoma, gastroesophageal junction adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab head and neck squamous cell carcinoma (HNSCC) Reimburse with clinical criteria and/or conditions Complete